Petter Segelman Lindqvist appointed new CEO of Hamlet Pharma
Hamlet Pharma, soon to be Hamlet BioPharma, the innovative pharmaceutical company with several projects in Phase II trials in infection and cancer and an extensive project and patent portfolio, announces the appointment of Petter Segelman Lindqvist as new CEO, starting October 1st 2023.
The recruitment of Petter Segelman Lindqvist marks a new phase in the development of Hamlet BioPharma’s groundbreaking technologies for cancer and infection therapy. Petter Segelman Lindqvist’s extensive experience from the global pharmaceutical Industry will increase the emphasis on partnering, commercialization and future market approval. The board wishes to thank Martin Erixon, who will stay as CEO until Petter Segelman Lindqvist joins the company in the fall of 2023.
Petter Segelman Lindqvist, with a background at pharmaceutical companies such as GlaxoSmithKline, Abbott and AbbVie, is currently holding a position as Portfolio Strategy Lead at Sobi (Swedish Orphan Biovitrum AB). He brings significant experience from the Global Strategy and Corporate Development functions, as well as from roles in global commercial operations and product strategy. Petter Segelman Lindqvist holds an MSc in Economics and Business Administration from the Stockholm School of Economics and EM Lyon, France.
"The Board would like to welcome Petter Segelman Lindqvist, who will strengthen the business development and deal-making capabilities of the company in the pharmaceutical industry sector and to thank Martin Erixon for his contributions to the company, not least during the recent merger of Hamlet Pharma with SelectImmune Pharma. Petter Segelman Lindqvist’s background in the global pharmaceutical industry will be essential to develop our rich pipeline of molecules into useful treatments" comments Catharina Svanborg, Chairman.
"I look forward to working with the board of directors and the team at Hamlet Pharma in developing the company to reach its full potential and to further accelerate the efforts to bring the products closer to the market. The science behind the new drug candidates is truly impressive and now is the time to advance the projects to reach patients in need of new treatments for cancer and infection”, says Petter Segelman Lindqvist.
This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-06-2023 09:25 CET.
